
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA focuses on developing innovative therapies and diagnostics for neurodegenerative diseases, leveraging proprietary technologies to target misfolded proteins. The company's pipeline, which includes promising candidates like ACI-7104.056 and ACI-24, has shown significant early results, such as a 20-fold increase in antibodies against pathogenic variants and stabilization of critical neurological markers, indicating strong therapeutic potential. The impending release of data on plaque removal for ACI-24 is anticipated to be a key catalyst, particularly for addressing high-risk patients, thereby enhancing the company's position in the Alzheimer's treatment landscape.
Bears say
AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, reflecting the substantial financial challenges the company is currently facing. Additionally, the company's net loss for the year 2025 reached CHF 70.4 million, with basic and diluted earnings per share (EPS) recorded at (0.70), indicating a negative return on investment for shareholders. The company also contends with inherent industry risks, including potential negative outcomes from clinical trials, regulatory uncertainties, and the complexities of price-sensitive commercial markets for its product candidates.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares